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Cost-EffECtivENEss ANAlysis of AbirAtEroNE ACEtAtE trEAtmENt 
ComPArEd with CAbACitAxEl iN domiNiCAN rEPubliC, iN PAtiENts with 
mEtAstAtiC CAstrAtioN-rEsistANt ProstAtE CANCEr thAt hAvE fAilEd 
to ChEmothErAPy with doCEtAxEl
Obando C.A.1, Desanvicente-Celis Z.1, Gonzalez L.2, Muschett D.1, Gonzalez F.1, Goldberg P.1
1Janssen, Panama, Panama, 2Janssen, Raritan, NJ, USA
Objectives: To assess the cost-effectiveness of Abiraterone Acetate plus Prednisone 
(A-P) compared with Cabazitaxel plus Prednisone (C-P) in Dominican Republic, in 
patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) that have 
failed to chemotherapy with Docetaxel. MethOds: A three-health state cohort sim-
ulation Markov Model (progression-free, post-progression and death) was developed 
based on overall and progression free survival data. The time frame was 10 years. 
The perspective was that of the Public System of Health of Dominican Republic. The 
health outcomes of interest were Quality Adjusted Life Years (QALYs) and Life Years 
(LYs). Efficacy data was taken from clinical trials (COU-AA-301 for A-P and TROPIC 
for C-P). Utilities for health states and negative utilities for adverse events were 
estimated based on quality of life endpoints of the COU-AA-301 trial. The base year 
was 2012. All costs are presented in Dominican currency (Dominican Pesos - RD$). 
Costs and outcomes were discounted at 5%. Probabilistic sensitivity (PSA) analysis 
was performed to evaluate uncertainty surrounding the parameters. Results: 
A-P resulted in 0.79 QALYs and 1.35 LYs, per patient, respectively. C-P resulted in 0.71 
QALYs and 1.28 LYs, per patient, respectively. Mean total costs per patient were: RD$ 
2.204.289 for A-P and RD$ 2.732.365 for C-P. The results of the probabilistic sensitivity 
analysis showed that, when compared with C-Z, A-P was found dominant (associ-
ated with reduced costs and increased QALYs) in the majority of the iterations. A-P 
had a 75% probability of being cost effective, independent of the willingness to pay, 
when compared to C-P. cOnclusiOns: A-P can be considered cost-saving (domi-
nant), when compared with C-P, in patients with Metastatic Castration-Resistant 
Prostate Cancer that have failed to chemotherapy with Docetaxel, from the perspec-
tive of the Public System of Health of Dominican Republic.
PCN122
CliNiCAl ANd ECoNomiC ANAlysis of EffECtivENEss of EvErolimus iN 
thE trEAtmENt of hr+, hEr2- AdvANCEd brEAst CANCEr iN russiA
Krasnova L., Vorobiev P., Holownia M.
Russian Society for Pharmacoeconomics and Outcomes Research, Moscow, Russia
Objectives: Modern therapeutic approaches in treatment of advanced breast 
cancer can achieve clinically significant regression of symptoms, prolong life and 
improve its quality. Aim of this study was to conduct clinical and economic analysis 
of application of everolimus in the treatment of hormone-receptor-positive (HR+), 
human epidermal growth factor receptor-2-negative (HER2-) advanced breast can-
cer in postmenopausal women. MethOds: An epidemiological and pharmaco-
economic evaluation of HR+, HER2- advanced breast cancer in postmenopausal 
women with using a survey of experts from different regions of Russia and mod-
eling method. Calculating the cost of drugs and medical services was conducted 
according to experts and standard of medical care. Filling of a Markov model was 
conducted without using and with using of everolimus in the treatment of the 
patients within 5 years. Calculated indicators were: the impact of the disease on 
budget, the cost of one additional year of life. Results: From 13 regions of Russia 
8 experts refused to provide information on the questionnaire, which may indicate 
the unwillingness to disclose information on epidemiology and tactics of treatment 
of disease. The burden of breast cancer for 5 years without the use of everolimus 
in the treatment regimens of patients with postmenopausal HR+, HER2- advanced 
breast cancer and with using it were: in Moscow 118.668.419€ and 137.596.651€ ; 
St. Petersburg-36.730.318€ and 38.133.492€ ; Republic of Khakassia-18.854.270€ and 
19.812.467€ ; Omsk region-32.428.540€ and 33.603.456€ ; Primorsky Krai-39.176.077€ 
and 40.877.880€ . The use of of everolimus with exemestane in the treatment of 
advanced breast cancer increases by 1.5-2 times life expectancy and its “cost-effec-
tiveness” indicator is 2 times lower comparing to exemestane monotherapy and 
chemotherapy. Sensitivity analysis using the results from 5 regions of Russia showed 
unidirectional comparison. cOnclusiOns: The use of everolimus with exemestane 
is the dominant technology of treatment HR+, HER2- advanced breast cancer in 
postmenopausal patients compared with traditional technology of application of 
chemotherapy drugs or exemestane alone.
PCN123
A Cost-EffECtivENEss ANAlysis of EGfr-tK mutAtioN stAtus-GuidEd 
1st- ANd 2Nd-liNE trEAtmENt of stAGE iii/iv NoN-smAll CEll luNG 
CANCEr iN thE uK
Patel K., Montouchet C., Cheynel J., Ruff L.
Covance Inc., London, UK
Objectives: Lung cancers are the most common malignant tumours, account-
ing for 1.38 million annual deaths worldwide. Non-small cell lung cancer (NSCLC), 
the predominant tumour subtype, is associated with significant deteriorations in 
both survival and quality of life. Epidermal growth factor receptor tyrosine kinase 
(EGFR-TK) has emerged as a drug therapy target. The National Institute for Health 
and Care Excellence (NICE) recommends erlotinib – an EGFR-TK inhibitor – for 
first-line treatment of NSCLC in EGFR-TK mutation-positive patients, and second-
line treatment in all patients irrespective of EGFR-TK mutations. We developed 
a model to assess the cost-effectiveness of an EGFR-TK mutation status-guided 
treatment strategy for stage III/IV NSCLC, compared with a strategy not depend-
ent on mutational status. MethOds: A Markov model was developed from the 
perspective of the UK National Health Service (NHS) over a lifetime horizon. This 
compared a current scenario (in which a cohort of NSCLC patients received dou-
blet chemotherapy at first-line therapy, followed either by erlotinib or docetaxel at 
second-line) to a revised scenario (in which all EGFR-TK mutation-positive patients 
received erlotinib at first-line followed by second-line docetaxel, and all mutation-
negative patients received doublet chemotherapy followed by either docetaxel or 
Markov model was developed to estimate the health outcome (QALY) and total 
treatment costs with Markov cycle of 21 days and lifetime horizon. The effec-
tiveness data was retrieved from the randomized clinical trial ECOG 4599. Direct 
costs, including cost of drugs, administration, medical services, hospital bed day 
and adverse drug reaction management were estimated based on treatment 
guideline of NCCN for NSCLC. Indirect costs, including loss of earnings, cost for 
meal, transportation, accomodation of patients and their caregivers due to treat-
ment, were estimated based on survey of a cohort of 87 patients with NSCLC 
in HCMC Oncology Hospital. Both cost and effectiveness were discounted 3% 
annually. Results: Adding bevacizumab to PC regimen in first-line therapy of 
advanced NSCLC patients resulted in incremental QALY gained of 2.26 month 
compared with PC regimen (7.88 versus 5.62). The total treatment cost with BCP 
was 3 times higher than PC (2,499 millions vs 761.7 millions VND, respectively). 
ICER of BCP versus PC was 768,732,924 VND, which is 3.35 times higher than the 
Willingness-To-Pay of Vietnam in 2013 (229,242,416 VND). A probability sensitivity 
analysis demonstrated the patient’s weight and bevacizumab’s price as the most 
affecting factors to the ICER of BCP vs PC. cOnclusiOns: Conducted analysis 
showed that combination of bevacizumab and PC regimen in first-line therapy 
of NSCLC was not cost-effective compared with PC regimen. Support from the 
manufactures, suppliers and insurance organizations are neccessary to raise its 
economic effectiveness in treatment of advanced NSCLC.
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Cost-EffECtivENEss simulAtioN of ColoNoGrAPhy vErsus 
ColoNosCoPy iN GErmANy: is lAxAtivE-frEE ColoNoGrAPhy Cost-
EffECtivE?
Kriza C.1, Jahn B.2, Hassan C.3, Kolominsky-Rabas P.L.1
1Centre for Health Technology Assessment (HTA) and Public Health (IZPH), Friedrich-Alexander-
University Erlangen-Nürnberg, Erlangen, Germany, 2UMIT - University for Health Sciences, 
Medical Informatics and Technology, Hall in Tyrol, Austria, 3Nuovo Regina Margherita Hospital, 
Rome, Italy
Objectives: Colorectal cancer (CRC) screening using computerised tomographic 
colonography (CTC), also referred to as virtual colonography, has attracted consider-
able attention due to its positive impact on high screening uptake rates, especially 
with a laxative-free preparation before screening. A decision analysis model was 
constructed in order to evaluate the clinical and economic consequences of per-
forming three different screening tests versus a no screening scenario in a popula-
tion at average risk of colorectal cancer in Germany: colonoscopy, conventional 
CT-colonography and laxative-free CT colonography. MethOds: A state-transition 
microsimulation was developed for the evaluation of the different screening strate-
gies using TreeAge Pro Healthcare 2014. A hypothetic population of 100,000 German 
asymptomatic adults aged between 50 and 100 years was used for the basis of the 
model. The simulation of the screening strategies was undertaken by assessing the 
number of screening patients diagnosed with CRC on the basis of the sensitivity 
and specificity of each strategy and the related uptake of each screening method. 
Sensitivity analysis will be applied to test the impact of parameter uncertainty on 
model outcomes and recommendations. Results: Initial results of the simula-
tion show that laxative-free colonography was found to be the most costly screen-
ing option, with a total cost of EUR 4,115 per screening patient in the simulation 
model. Colonoscopy was found to be the least costly screening method, with total 
equivalent costs of EUR 2,132. The most effective screening was modeled for laxa-
tive-free colonography. The ICER of laxative-free colonography compared to colonos-
copy was simulated at 5,221 EUR per life year saved. cOnclusiOns: Our simulation 
has shown that using data from new research indicating the possibility of less costly 
use of CTC than previously used for modeling, laxative-free CTC screening has the 
potential to become a cost-effective alternative screening method for CRC due to 
its advantage related to improvements in screening uptake.
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Cost-EffECtivENEss ANAlysis of AbirAtEroNE ACEtAtE trEAtmENt 
ComPArEd with CAbACitAxEl iN CostA riCA, iN PAtiENts with 
mEtAstAtiC CAstrAtioN-rEsistANt ProstAtE CANCEr thAt hAvE fAilEd 
to ChEmothErAPy with doCEtAxEl
Obando C.A.1, Desanvicente-Celis Z.1, Gonzalez L.2, Muschett D.1, Gonzalez F.1, Goldberg P.1
1Janssen, Panama, Panama, 2Janssen, Raritan, NJ, USA
Objectives: To assess the cost-effectiveness of Abiraterone Acetate plus Prednisone 
(A-P) compared with Cabazitaxel plus Prednisone (C-P) in Costa Rica, in patients 
with Metastatic Castration-Resistant Prostate Cancer (mCRPC) that have failed to 
chemotherapy with Docetaxel. MethOds: A three-health state cohort simula-
tion Markov Model (progression-free, post-progression and death) was developed 
based on overall and progression free survival data. The time frame was 10 years. 
The perspective was that of the Public System of Health of Costa Rica. The health 
outcomes of interest were Quality Adjusted Life Years (QALYs) and Life Years (LYs). 
Efficacy data was taken from clinical trials (COU-AA-301 for A-P and TROPIC for C-P). 
Utilities for health states and negative utilities for adverse events were estimated 
based on quality of life endpoints of the COU-AA-301 trial. The base year was 2012. 
All costs are presented in Costa Rican currency (Colones - CRC). Costs and outcomes 
were discounted at 5%. Probabilistic sensitivity (PSA) analysis was performed to 
evaluate uncertainty surrounding the parameters. Results: A-P resulted in 0.79 
QALYs and 1.35 LYs, per patient, respectively. C-P resulted in 0.71 QALYs and 1.28 
LYs, per patient, respectively. Mean total costs per patient were: CRC 33.881.184 for 
A-P and CRC 41.981.207 for C-P. The results of the probabilistic sensitivity analysis 
showed that, when compared with C-Z, A-P was found dominant (associated with 
reduced costs and increased QALYs) in the majority of the iterations. A-P had an 
89% probability of being cost effective, independent of the willingness to pay, when 
compared to C-P. cOnclusiOns: A-P can be considered dominant (cost-saving), 
when compared with C-P, in patients with Metastatic Castration-Resistant Prostate 
Cancer that have failed to chemotherapy with Docetaxel, from the perspective of 
the Public System of Health of Costa Rica.
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(MMR). The model assumes stabilized prices of second-generation TKIs, but dis-
counts the price of imatinib: 100% for first 6-months; 60-80% for second 6-months; 
and 10-30% thereafter. For each drug, tolerance, efficacy and the probabilities of 
treatment choice, switching and failure were drawn from published clinical tri-
als. Quality-adjusted life years (QALYs) were based on U. K. preference weights 
(Szabo et al. 2010). According to Hoyle et al. (2011), direct medical costs per patient 
were: £20,244 for imatinib; and ~£30,000 for dasatinib and nilotinib. Additional 
costs included patient monitoring and allogeneic transplantation. Costs and QALYs 
were discounted at 3% (British Pounds Sterling (£); 2013). Sensitivity analyses tested 
parameters for impact on results at a willingness-to-pay of £50,000/QALY. Results: 
Step-therapy costs less and offers clinically-equivalent utility (£62,388; 2.864 QALYs) 
compared to physician-choice (£71,268; 2.879 QALYs), at an ICER of £592,000/QALY. 
The results are robust to changes based on univariate analyses of each parameter. 
Multivariate probabilistic sensitivity analyses found step-therapy cost-effective 
in 99.9% of 10,000 Monte Carlo simulations. cOnclusiOns: When imatinib loses 
patient protection between 2015-2016 throughout Europe, it will be the cost-effective 
initial treatment strategy for CML compared to second-generation TKIs.
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litErAturE rEviEw of dECisioN-ANAlytiCAl modEls usEd iN thE 
ECoNomiC EvAluAtioN of EmPiriCAl/tArGEtEd ANtifuNGAl trEAtmENts 
for iNvAsivE fuNGAl iNfECtioNs
Buyukkaramikli N.C.1, Gaultney J.2, Leunis A.1, Severens J.L.1
1Institute for Medical Techonology Assessment (iMTA), Rotterdam, The Netherlands, 2Mapi Group, 
Houten, The Netherlands
bAckgROund: Invasive fungal infections (IFIs) are an important cause of morbidity 
and mortality in immunocompromised patients. Based on the pathogen identifica-
tion status, either empirical (without diagnosis) or targeted (with diagnosis) anti-
fungal therapy is administered to symptomatic patients (e.g. with fever). Several 
antifungal agents are available and their cost-effectiveness is often evaluated 
using decision analytic models (DAMs). Objectives: The objective was to review 
all published DAMs used in economic evaluations of empirical/targeted antifungal 
treatments for IFIs. This approach is novel as previous reviews were either patho-
gen or agent-specific. MethOds: A review was conducted in MEDLINE/EMBASE 
to identify all economic evaluations that included DAMs published until 1-1-2014. 
Previous reviews were checked for additional studies. Non-English and studies of 
prophylactic treatment were excluded. Data extracted included: population, indica-
tion, comparators, model structure, time horizon, outcomes, events, year, country, 
and sponsorship. Results: Overall, 24 published economic evaluations including 
a DAM were identified. 54% (n= 13) were for targeted treatments and the remaining 
(n= 11) for empirical treatments. 62% of the DAMs on targeted treatments (n= 8) 
focused on invasive pulmonary aspergillosis and the remaining 38% (n= 5) on inva-
sive candiasis/candidemia. The majority (73%, n= 8) of DAMs evaluating empirical 
treatments focused on patients with persistent fever/febrile neutropenia. Lipid for-
mulation amphotericin-B was a comparator in 46% (n= 11) of the studies, followed by 
caspofungin in 42% (n= 10) and voriconazole in 42% (n= 10). 92% of the DAMs (n= 22) 
included only a decision tree, whereas the remaining 8% (n= 2) embedded a life-
time Markov model. The majority (54%, n= 13) had a hospital perspective and time 
horizon of less than 12 weeks (54%, n= 14). Only one study utilized real-world data.  
cOnclusiOns: There are major differences in the modeling approach, time horizon, 
comparator (s), treatment sequences and outcomes of published economic evalu-
ations in IFI. A list of minimal, consensus-based methodological and structural 
requirements for DAMs on antifungal treatments of IFIs, elicited from key experts 
is needed.
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ExPANsioN of thE NorwEGiAN hPv vACCiNAtioN ProGrAm
Sæterdal I., Juvet L., Jimenez E., Couto E., Klemp M., Torkilseng E.B.
Norwegian Knowledge Centre for the Health Services, Oslo, Norway
Objectives: To evaluate the cost-effectiveness of expanding the Norwegian HPV 
vaccination program to catch-up females and 12 years old boys. MethOds: We 
systematically searched the literature for randomized clinical trials (RCTs) that exam-
ined the effect of HPV vaccines on cancer mortality and incidence, precancerous 
stages and serious adverse events. We assessed selected publications for potential 
risk of bias, and the overall quality of the evidence for each outcome using GRADE. 
We adapted a published economic model to the Norwegian setting with respect to 
incidence of HPV-related outcomes, costs and quality adjusted life years (QALYs) 
lost from HPV-related diseases. The cost utility analysis reported results in Euros/
QALY gained in both a public health budget and a societal perspective. Results: We 
included 46 publications reporting on 13 RCTs for young women, and 3 on 2 RCT for 
boys (maximum follow-up period: three-four years). We found a borderline protective 
effect of HPV catch-up vaccination on all CIN2+, with a pooled risk ratio (RR) of 0.80 
(95% CI: 0.62-1.02) for a follow-up period of 4 years. HPV catch-up vaccination was 
associated with a reduction in VIN2+ and VaIN2+ lesions, and genital warts. No dif-
ference in risk of serious adverse events was seen in vaccinated participants versus 
unvaccinated women (pooled RR of 0.99 (0.91-1.08)). We are currently reviewing the 
studies on boys. From a public health budget perspective, catch-up vaccination led 
to higher costs and health gains and an ICER= 70371€ . From a societal perspective, 
the incremental costs were lower, resulting in an ICER= 67365€ . cOnclusiOns: This 
systematic review indicates that a HPV catch-up vaccination could be beneficial and 
cost-effective for young women. The long-term effect of such a vaccination, and its 
effect on cancer incidence and mortality is still unclear.
PCN129
Cost-EffECtivENEss of rAdiCAl ProstAtECtomy, rAdiAtioN thErAPy 
ANd ACtivE survEillANCE for thE trEAtmENt of loCAlizEd ProstAtE 
CANCEr – A ClAims dAtA ANAlysis
Brandes A.1, Koerber F.1, Schwarzkopf L.1, Hunger M.1, Waidelich R.2, Rogowski W.1
1Helmholtz Zentrum München, Neuherberg, Germany, 2University of Munich, Munich, Germany
erlotinib). Efficacy data were based on the TORCH and TAX317 randomised con-
trolled trials. Cost data were obtained from NHS Reference Costs, British National 
Formulary list prices and other publically-available sources. Results: In the base-
case analysis, the estimated incremental cost-effectiveness ratio exceeded the 
NICE willingness-to-pay threshold of £20,000 per quality-adjusted life year gained. 
Univariate and probabilistic sensitivity analyses suggested the results were robust 
to parameter changes, showing greatest sensitivity to variation in overall survival 
parameters. cOnclusiOns: Our model suggests that, from the perspective of the 
UK NHS, an EGFR-TK mutation status-guided treatment strategy across first- and 
second-line treatment of NSCLC is not cost-effective compared with a strategy not 
dependent on mutational status.
PCN124
ComPArAtivE Cost-EffECtivENEss study of modErN rAdiAtioN 
thErAPiEs iN huNGAry for loCAlizEd ProstAtE CANCEr
Zemplényi A.1, Kalo Z.2, Mangel L.1, Endrei D.1, Boncz I.3
1University of Pécs, Pécs, Hungary, 2Eötvös Loránd University (ELTE), Budapest, Hungary, 3Faculty 
of Health Sciences, University of Pécs, Pécs, Hungary
Objectives: The introduction of innovative medical devices with high investment 
and operational costs is often delayed in countries with severe resource constraints. 
Cost-effectiveness analysis can help decision-makers to understand the economic 
value of such technologies. The purpose of our study was to compare the cost-effec-
tiveness of two modern radiation therapy techniques, the stereotactic body radiation 
therapy (SBRT) and intensity-modulated radiation therapy (IMRT) compared to the 
3-dimensional conventional radiation therapy (3DCRT) for treatment of low- to 
intermediate-risk prostate cancer in Hungary. MethOds: A Markov model was 
constructed with the following disease states of a 65-year-old patient with organ 
confined prostate cancer: no evidence of disease after radiation therapy, hormone 
therapy, chemotherapy, death. Transition probabilities were calculated based on 
the international literature for SBRT, IMRT and 3DCRT. Utility values for each health 
state were obtained from publically available secondary sources. Costs in the model 
were calculated based on the Hungarian Health Insurance Fund rates, and were 
converted to EUR by applying actual exchange rates (1 EUR = 305 HUF). Analysis 
was conducted from payer perspective for 65-year-old patients over 10 years time 
horizon. Results: Based on preliminary calculations the expected mean cost of 
patients undergoing SBRT, IMRT and 3DCRT were 2,201 EUR, 5,704 EUR and 11.549 
EUR respectively. Expected QALYs were 6.00 for SBRT, 5.8 for IMRT and 3.9 for 3DCRT. 
Compared to 3DCRT, both IMRT and SBRT were less costly and resulted in more 
health gain. cOnclusiOns: The modern SBRT and IMRT are not only cost-effective 
compared to the conventional 3DCRT but also provide a great cost saving potential 
for the Hungarian health care system and may improve access to radiation and qual-
ity of life for patients. Appropriate financial incentives in the DRG system should 
support the uptake of cost-effective hospital technologies in Hungary.
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systEmAtiC CritiCAl rEviEw of ECoNomiC EvAluAtioNs of rituximAb, 
AddEd to CoNvENtioNAl ChEmothErAPy rEGimEN iN thE trEAtmENt of 
PAtiENts with ChroNiC lymPhoCytiC lEuKEmiC rEfrACtory
Koury C.D.N.1, Nunes A.A.2, Nita M.1
1FIPE -Fundação de Ensino e Pesquisas Econômicas, Brasilia, Brazil, 2University of São Paulo - 
USP, Ribeirão Preto, Brazil
Objectives: To review the cost-effectiveness studies of chronic lymphocytic leu-
kemia (CLL) treatment, in combination and in comparison with fludarabine and 
cyclophosphamide chemotherapy (R-FC) in refractory patients or patients who had 
been previously treated. MethOds: Search and analysis of scientific evidence: 
the basics of The Cochrane Library, Centre for Reviews and Dissemination (CRD), 
Embase, Lilacs, Database of the Brazilian Network for Technology Assessment 
(SISREBRATS), and MEDLINE via PubMed were searched. Aiming to meet economic 
evaluations (AVE), or evaluations of health technologies (ATS), comparing schemas 
cyclophosphamide and fludarabine (CF) and the same plus Rituximab (R-FC). Studies 
were only selected in second-line treatment for CLL. Results: Two economic evalu-
ations studied the treatment of patients with refractory or relapsing disease (R-FC 
vs FC). In the study, 24% had improvement in progression-free survival outcome (p 
< 0.05) in the R-FC, with more patients achieving partial or complete response in 
this group (61% vs 49%, p < 0.05). There was no statistically significant difference in 
overall survival. The Rituximab caused more adverse effects, but values of statistical 
tests for these outcomes are not presented. In a technology assessment conducted 
by NICE, even with reservations, the drug was recommended in view of the British 
health care system. cOnclusiOns: There is significant uncertainty in the relevant 
outcomes for stages of refractory or relapsing disease. Few clinical trials evaluating 
the effectiveness of Rituximab in patients with CLL, which demonstrate no impact 
on overall survival, were found. In addition to the significant increase in costs for 
managing the disease.
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whAt is thE most Cost-EffECtivE strAtEGy for trEAtiNG ChroNiC 
myEloid lEuKEmiA AftEr imAtiNib losEs PAtENt ExClusivity iN EuroPE?
Padula W.V.1, Conti R.2, Larson R.1
1University of Chicago, Chicago, IL, USA, 2University of Chicago, Chicago, GA, USA
Objectives: To analyze the cost-effectiveness of treating all chronic-phase chronic 
myeloid leukemia (CML) with imatinib initially compared to physician-choice 
between imatinib or the second-generation tyrosine kinase inhibitors (TKIs) dasat-
inib or nilotinib. Imatinib will lose patent exclusivity between 2015-2016 and its 
price is expected to drop 60-90% within one year throughout Europe. MethOds: 
A Markov model simulating “step-therapy” compared to “physician-choice” in 
treating CML in 2015 through 5 years. The model assumes a European societal per-
spective. In both approaches, if initial treatment fails, patients are switched to a 
second-generation TKI. Patients are assumed to switch if they fail to meet efficacy 
endpoints: complete cytogenetic response (CCyR) or major molecular response 
